The BRAFV600E mutation analysis and risk stratification in papillary thyroid carcinoma
Rafael Selbach Scheffel, Ana Patrícia de Cristo, Mírian Romitti, Carla Vaz Ferreira Vargas, Lucieli Ceolin, André Borsatto Zanella, José Miguel Dora, Ana Luiza Maia
Abstract
OBJECTIVE: mutation status on PTC risk stratification. METHODS: mutation status information was evaluated. RESULTS: mutation and persistent disease status (RR 0.96; 95%CI 0.47-1.94). Notably, none of the patients reclassified from low to intermediate risk showed persistent disease on follow-up. CONCLUSION: mutational status has a limited impact on risk stratification and does not add to the prediction of outcomes in PTC patients.
Topics & Concepts
MedicineRisk stratificationInternal medicineThyroid carcinomaMutationDiseaseOncologyPapillary thyroid cancerThyroid cancerGastroenterologyCancerThyroidGeneticsGeneBiologyThyroid Cancer Diagnosis and TreatmentS100 Proteins and Annexins